MiMedx Group (MDXG) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.01
- Estimate
- —
- Surprise
- —
- Revenue (period 2026-09-30)
- $62.3M
- Score at report (before → after)
- 5.1 → 5.2/10
Revenue source: xbrl.
How the report landed
TrendMatrix's engine moved from Buy (Wait) (5.1/10) to Sell at 5.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates MDXG Sell at 5.2/10.
1 of the last 4 quarters beat the estimate.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Analyst upside: 78%
What argues against it
- V7 low-quality RISK_OFF penalty: -0.5 (Q=4.9)
- Consecutive earnings misses (2)
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.62
- Price target
- $6.44
- Stop
- $3.46
- Upside to target
- +78.1%
- Reward-to-risk
- 6.3:1
The stock trades at 98.8× trailing but 37.6× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 23 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
MDXG at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $576.4M
- P/E (fwd)
- 37.6
- P/E (ttm)
- 98.8
- 52-week range
- $3.03–$7.97
- Off 52-week high
- 54.6%
- RSI (14)
- 23
- Volume vs avg
- 0.16×
- Score today
- 5.2/10